V89L polymorphism of the 5α-reductase type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 2, 2008, Pages 286-291

  Boger Megiddo, Inbal ^a,b   Weiss, Noel S ^a,b   Barnett, Matt J ^a   Goodman, Gary E ^a,c   Chen, Chu ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SWEDISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANEDIOL; ANDROSTANEDIOL GLUCURONIDE; ANDROSTENEDIONE; ESTRADIOL; PRASTERONE SULFATE; STEROID 5ALPHA REDUCTASE 2; TESTOSTERONE; UNCLASSIFIED DRUG; SEX HORMONE; STEROID 5ALPHA REDUCTASE;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; GENETIC POLYMORPHISM; GENOTYPE; HORMONE BLOOD LEVEL; HUMAN; MALE; MEN'S HEALTH; PRIORITY JOURNAL; PROSTATE CANCER; BLOOD; CASE CONTROL STUDY; GENETICS; MIDDLE AGED; PROSTATE TUMOR; RISK FACTOR; STATISTICAL MODEL;

AGED; CASE-CONTROL STUDIES; GENOTYPE; GONADAL STEROID HORMONES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 39449083160     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0238     Document Type: Article

References (24)

1. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 2002 Incidence and Mortality. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2005.
2. Wilding G. Endocrine control of prostate cancer. Cancer Surv 1995;23:43-62.
3. Damber JE. Endocrine therapy for prostate cancer. Acta Oncol 2005;44:605-9.
4. Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev 1993;2:27-32.
5. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-26.
6. Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res 1990;50:169-73.
7. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002;52:213-35.
8. Chen C, Weiss NS, Stanczyk FZ, et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2003;12:1410-6.
9. Allen NE, Forrest MS, Key TJ. The association between polymorphisms in the CYP17 and 5α-reductase (SRD5A2) genes and serum androgen concentrations in men. Cancer Epidemiol Biomarkers Prev 2001;10:185-9.
10. Hsing AW, Chen C, Chokkalingam AP, et al. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2001;10:1077-82.
11. Febbo PG, Kantoff PW, Platz EA, et al. The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer. Cancer Res 1999;59:5878-81.
12. Lunn RM, Bell DA, Mohler JL, Taylor JA. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999;20:1727-31.
13. Li Z, Habuchi T, Mitsumori K, et al. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population. J Urol 2003;169:2378-81.
14. Nam RK, Toi A, Vesprini D, et al. V89L polymorphism of type-2, 5-α reductase enzyme gene predicts prostate cancer presence and progression. Urology 2001;57:199-204.
15. Salam MT, Ursin G, Skinner EC, Dessissa T, Reichardt JK. Associations between polymorphisms in the steroid 5-α reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol 2005;23:246-53.
16. Soderstrom T, Wadelius M, Andersson SO, et al. 5α-Reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 2002;12:307-12.
17. Lamharzi N, Johnson MM, Goodman G, et al. Polymorphic markers in the 5α-reductase type II gene and the incidence of prostate cancer. Int J Cancer 2003;105:480-3.
18. Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and β carotene on the incidence of lung cancer and other cancers in male smokers. The α-Tocopherol. N Engl J Med 1994;330:1029-35.
19. Omenn GS, Goodman G, Thornquist M, et al. The β-Carotene and Retinol Efficacy Trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. Cancer Res 1994;54:2038-43s.
20. Jarow JP, Wright WW, Brown TR, Yan X, Zirkin BR. Bioactivity of androgens within the testes and serum of normal men. J Androl 2005;26:343-8.
21. Labrie F, Belanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 1997;82:2396-402.
22. Nomura AM, Stemmermann GN, Chyou PH, Henderson BE, Stanczyk FZ. Serum androgens and prostate cancer. Cancer Epidemiol Biomarkers Prev 1996;5:621-5.
23. Dorgan JF, Albanes D, Virtamo J, et al. Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol Biomarkers Prev 1998;7:1069-74. Erratum in: Cancer Epidemiol Biomarkers Prev 1999;8:485.
24. Guess HA, Friedman GD, Sadler MC, et al. 5α-Reductase activity and prostate cancer: a case-control study using stored sera. Cancer Epidemiol Biomarkers Prev 1997;6:21-4.